Monday, October 1, 2001
During the past decade, researchers have identified thousands of
variations within the human genome valuable for diagnostic purposes. While many companies
have developed technologies to search for known variations in a patient's genome, Solexa Ltd. is taking the direct approach: sequencing the entire genome of a patient.
While the de novo sequencing of the human genome took several years,
thousands of scientists and millions of dollars, President Nick McCooke says that Solexa
(Cambridge, U.K.) is aiming to sequence an individual's genome within a couple of days and
for a few thousand dollars.